Background: Hereditary nonpolyposis colorectal cancer syndrome (HNPCC syndrome; also called Lynch syndrome) is one of the most common cancer predisposition syndromes. Most cases of cancer associated with this syndrome are due to the inheritance of germline mutations in genes that encode proteins required for DNA mismatch repair; defects in these proteins allow mutations to accumulate more rapidly in the DNA and influence the rate of cancer development. Recent studies indicate that the reactivation of the activity of telomerase, an enzyme involved in the synthesis of chromosomal ends, in somatic cells may play a role in carcinogenesis. In this study, we evaluated the expression of telomerase in normal and cancerous colorectal tissue specimens from HNPCC and non-HNPCC patients. Methods: The polymerase chain reaction-based telomeric repeat amplification protocol was used to assay telomerase activity in colorectal tissue specimens from 33 non-HNPCC patients (23 normal, 26 polyps, and 37 cancer specimens) and from 24 HNPCC patients (24 normal, 0 polyps, and 28 cancer specimens). Results: Thirtyone of 37 carcinoma samples from 18 non-HNPCC patients and 27 of 28 carcinoma samples from 24 HNPCC patients were found to be positive for telomerase activity. Whereas only one of 23 normal mucosa samples from 23 non-HNPCC patients was found to have (weak) telomerase activity, eight of 24 normal mucosa samples from 24 HNPCC patients were positive for telomerase; the difference between the two groups was statistically significant (two-sided P = .0226). Implication: This study generates the hypothesis that genetic defects in individuals with HNPCC syndrome facilitate the reactivation of telomerase activity, a process which may be associated with their predisposition to develop cancer. [J Natl Cancer Inst 1998;90:316-21]
Hereditary nonpolyposis colorectal cancer syndrome (HNPCC syndrome; also called Lynch syndrome) is one of the most common cancer predisposition syndromes and affects as many as one in 200 individuals in the Western world (1, 2) . This syndrome is inherited in an autosomal dominant fashion and is characterized by colonic and extra colonic tumors. The tumors in HNPCC patients have a characteristic replication error (RER + ) phenotype [reviewed in (3, 4) ]. Recent studies [reviewed in (3, 4) ] have shown that most cases of HNPCC are due to the inheritance of germline mutations in genes hMLH1, hMSH2, hPMS2, or hPMS1, which encode proteins required for DNA mismatch repair. During tumor development, the wild-type copy of the allele inherited from the unaffected parent is lost or mutated (5) (6) (7) . This event renders the affected cells completely deficient in mismatch repair, leading to a rapid accumulation of mutations and an accelerated rate of neoplastic progression (5, 6) .
Normal human somatic cells have a limited proliferative capacity (8) . Given the number of mutations required to produce colorectal carcinoma, the successive expansion of mutant clones is likely to involve cell divisions in excess of the limited proliferative capacity of somatic cells (6, 8) . Malignant cells, therefore, may acquire activity that overrides the control of senescence. Telomere length and telomerase activity have recently been implicated in the control of the proliferative capacity of normal and malignant cells (9) . Telomerase is a specialized ribonucleoprotein polymerase that synthesizes telomeric DNA onto chromosomal ends using a segment of its integral RNA component as a template (10) . Normal human somatic cells express low or undetectable telomerase activity and progressively lose their telomeric sequences with aging (11) . In contrast, most immortal cells contain telomerase activity and show no net loss of telomere sequence or length with cell division (12, 13) . Therefore, the telomerase activity appears to be stringently repressed in normal human somatic tissues but reactivated in immortal cells, suggesting that the up-regulation (i.e., increase in expression and/or activity) of telomerase may participate in cellular immortality. The possibility that the immortal cells in tumor develop as a consequence of telomerase reactivation has been recently examined in a number of cancers. All of the reported studies [reviewed in (14, 15) ] show that telomerase activity is detected in the majority of tumor specimens of most cancer types but rarely in normal tissue specimens. Therefore, telomerase activation appears to play an important role in carcinogenesis.
Although it is known that the defects of mismatch repair in individuals with HNPCC syndrome can lead to a rapid accumulation of mutations, little is known about the events that may account for their cancer predisposition. The recent finding that telomerase activation plays a role in carcinogenesis raises the possibility that the cancer susceptibility of HNPCC patients involves the activation of telomerase. Telomerase activity presumably allows cells to escape replicative senescence, thus eliminating one of the barriers to neoplastic progression. According to this postulate, the expression of telomerase in normal and precancerous tissues of HNPCC patients would differ from that of non-HNPCC patients. In this study, we assayed telomerase activity in normal and cancerous tissues obtained from HNPCC and other colorectal carcinoma patients.
Methods

Patients and Tissues
Colorectal tissue specimens from 33 non-HNPCC patients (23 normal, 26 polyps, and 37 cancer specimens) and from 24 HNPCC patients (24 normal, 0 polyps, and 28 cancer specimens) were collected during surgery at Chang Gung Memorial Hospital (Taiwan, Republic of China) and immediately frozen in liquid nitrogen or at −80°C. Written informed consent was obtained from all patients participating in the study. Most HNPCC tissue samples were collected during 1995 and 1996 (patients coded as H1-H20). For these patients, one tumor specimen and one piece of normal mucosa at least 10 cm away from the tumor were obtained. Tissue samples from four patients with HNPCC (patients coded as C1-C4), 18 with non-HNPCC cancers (patients coded as C5-C22), and 15 with adenomatous polyps (patients coded as P1-P15) were collected from January 1997 through April 1997. For these patients, one or more tumor specimens at different tumor sites and one piece of normal mucosa were obtained. The purpose of obtaining samples from different sites within the tumor was to determine whether there is a differential expression of telomerase activity in the malignant cells of a particular cancer. The main clinical and pathologic characteristics of non-HNPCC and HNPCC patients are shown in Tables 1 and 2 . Of the 33 non-HNPCC patients, 19 were male and 14 were female (mean age, 58 years). Of the 24 HNPCC patients, 13 were male and 11 were female (mean age, 55 years). The diagnosis, clinical stage, and anatomic site (colon or rectum) of the colorectal tumors were based on the International Union Against Cancer's TNM Classification of Malignant Tumors (16) . The tumors were histologically graded as well differentiated, moderately differentiated, and poorly differentiated based on the World Health Organization classification (17) . All of the patients diagnosed with HNPCC fulfilled the Amsterdam criteria proposed by the International Collaborative Group on HNPCC (ICG-HNPCC) (18) .
Cell Culture
HeLa cells, provided by C. Chao of the Biochemistry Department, Chang Gung University (Taiwan, Republic of China), were grown at 37°C in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum and antibiotics (100 U/mL penicillin, 100 U/mL streptomycin, and 0.25 g/mL amphotericin B) and in a humidified atmosphere containing 5% CO 2 ; these cells served as a positive control for the quantitation of telomerase activity. DMEM and antibiotics were purchased from Life Technologies, Inc. (GIBCO BRL), Gaithersburg, MD. Fetal bovine serum was from Boehringer Mannheim GmbH (Mannheim, Germany).
Telomerase Assay
Frozen tissue samples (100 g) were homogenized in 500 L of freshly made lysis buffer consisting of 10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 1 mM ethylene glycol-bis(␤-aminoethyl ether) N,N,NЈ,NЈ,-tetraacetic acid, 0.5% 3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propane sulfonate, 10% glycerol, 5 mM mercaptoethanol, and 0.1 mM phenylmethanesulphonyl fluoride in Kontes tubes (VWR Scientific Corp., Rochester, NY) with matching pestles rotated at 450 rpm. After 30 minutes of homogenization at 4°C, the lysates were centrifuged at 16 000g for an additional 30 minutes at 4°C. The supernatants were transferred to fresh tubes and used as tissue extracts for the telomerase assay. /L of lysis buffer and incubated on ice for 30 minutes. After centrifuging at 16 000g for 30 minutes at 4°C, the supernatants were transferred to fresh tubes and used as cell extracts for the telomerase assay. The protein concentrations were determined using Coomassie protein assay reagent (Pierce Chemical Co., Rockford, IL). Telomerase activity was assayed by the polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay (15) . In brief, aliquots of tissue extract containing 0.05-5 g protein were added to 50-L reaction mixtures containing 0.1 g TS oligonucleotide primer (5Ј-AATCCGTCGAGCAGAGTT-3Ј) (19) , 0.1 g CX oligonucleotide primer (5Ј-CCCTTACCCTTACCCTTACCCTAA-3Ј) (19), 2 U Taq DNA polymerase (HT Biotech. Ltd., U.K.), 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 63 mM KCl, 0.005% Tween 20, 1 mM EGTA, 50 M each of deoxyadenosine triphosphate, deoxyguanosine triphosphate, deoxycytidine triphosphate, and deoxythymidine triphosphate, and 0.1 mg/mL bovine serum albumin. The reaction mixtures were incubated at 24°C for 15 minutes and then amplified for 30 rounds of PCR at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1.5 minutes in a DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT). RNase digestion was performed as a control by the addition of RNase A (Sigma Chemical Co., St. Louis, MO) to the above reaction mixture at 10 g/mL. The PCR products were resolved by electrophoresis in a nondenaturing 12% polyacrylamide gel electrophoresis (PAGE) in a buffer containing 54 mM Tris-HCl (pH 8.0), 54 mM boric acid, and 1.2 mM EDTA. The gel was stained with SyBr green DNA stain (Molecular Probes, Inc., Eugene, OR), visualized, and photographed by illuminating with 254-nm UV light. Positive telomerase activity in an extract was determined by the presence of a sixnucleotide ladder of TRAP assay products in PAGE that were sensitive to RNase A treatment. For each run of the assay, three concentrations of HeLa extract protein, ranging from 0.005 to 0.5 g per 50 L reaction mixture, were assayed in parallel to serve as positive controls for comparison. The level of telomerase activity in a tissue extract was determined by referring the data obtained from 0.5 g of protein extract as follows: the band intensity of TRAP assay products on PAGE was compared with that from the HeLa cells. Telomerase activity was scored as strongly positive when the band intensity was greater than or equal to that produced by 0.5 g HeLa extract, moderately positive if equivalent to between 0.5 and 0.05 g HeLa extract, weakly positive if equivalent to between 0.05 and 0.005 g HeLa extract, or negative when less than that produced by 0.005 g HeLa extract. Each tissue sample was randomly assigned a code number then assayed for telomerase activity in a blinded manner. The clinical data were decoded for analysis of associations with telomerase activity only after the assays were completed.
Statistical Analysis
Fisher's exact test was used to examine the difference in the proportion of telomerase-positive specimens between the two groups with unmatched data, since the expected counts in two-way contingency tables were less than 5. The McNemar test was used to assess the difference in the proportion of telomerasepositive specimens between the two groups with matched data (20) . Reported P values are two-sided. A P value less than or equal to .05 was considered to be statistically significant. Exact or normal approximation methods were used to compute 95% confidence intervals (CIs) for proportion estimates (21) .
Results
Fig . 1 shows the TRAP results obtained from several tissues samples from a non-HNPCC patient. As shown in Fig. 1 , normal mucosa and polyp scored negative for telomerase activity, and two different sites of the cancer scored strongly positive (T1) and weakly positive (T2). Fig. 2 illustrates the results obtained from two HNPCC patients. The normal mucosa and tumor from patient H12 were moderately positive. The normal mucosa from patient H13 was telomerase negative, but the tumor tissue scored strongly positive. The TRAP results from all non-HNPCC and HNPCC patients as well as the main clinical and pathologic characteristics of the patients are shown in Tables 1 and 2 . All data regarding telomerase activity in normal mucosa, polyps, and cancer tissues from HNPCC and non-HNPCC patients are shown in Table 3 . In patients who do not have HNPCC syndrome and are diagnosed as having carcinoma (non-HNPCC/C, Table 3 ), positive telomerase activity (including weakly, moderately, and strongly positive) was found in 31 (84%; 95% CI ‫ס‬ 72%-96%) of 37 carcinoma tissue specimens, in two (33%; 95% CI ‫ס‬ 6%-81%) of six polyp tissue specimens, and in one (6%; 95% CI ‫ס‬ 0%-29%) of 17 normal tissue specimens. In patients who do not have HNPCC syndrome and are diagnosed as having adenomatous polyps (non-HNPCC/P, Table 3 ), positive telomerase activity was found in three (15%; 95% CI ‫ס‬ 4%-38%) of 20 polyp tissue specimens and in 0 (0%; 95% CI ‫ס‬ 0%-48%) of six normal tissue specimens. In HNPCC patients, positive telomerase activity was found in 27 (96%; 95% CI ‫ס‬ 83%-100%) of 28 carcinoma tissue specimens and in eight (33%; 95% CI ‫ס‬ 17%-55%) of 24 normal tissue specimens. Telomerase activity in different tissues from the same patient. Statistically significant differences were not seen between normal and polyp tissues for either the non-HNPCC patients with carcinoma (patients C17-C22; However, in non-HNPCC patients with carcinoma (patients C17-C22), significantly more telomerase-positive specimens were found in carcinoma tissues than in normal tissues (P for McNemar test <.0001) or polyps (P for McNemar test ‫ס‬ .0236). Similarly, significantly more telomerase-positive specimens were seen in carcinoma tissues than in normal mucosa from HNPCC patients (patients H1-H20 and C1-C4; Table 2 ) (P for McNemar test <.0001).
Telomerase activity in non-HNPCC patients. Among 37 carcinoma samples from 18 non-HNPCC cancer patients (patients C5-C22; Table 1 ), 31 were positive (including weakly, moderately, and strongly positive) for telomerase activity (Table  3) . Interestingly, we observed that tissue samples obtained from different locations of the same cancer contained different levels of telomerase activity ( Fig. 1; Table 1 ). The different levels of activity may result from the heterogeneity of tumor cells or from the regional capability of colon tumors to proliferate (22) . Because several samples from each cancer were tested with use of the TRAP assay, colorectal cancers from all 18 patients showed some telomerase activity, even if an occasional individual sample was negative. These results suggest that to increase the accuracy of telomerase detection in cancer, multiple samples should be obtained and assayed for this activity. Of the 26 polyp samples obtained from 21 non-HNPCC patients (patients C17-C22 and P1-P15), 21 were found to be negative and five were weakly positive for telomerase activity ( Table 1) . Two of the five telomerase-positive polyps were obtained from patients who had large colorectal carcinomas (patients C18 and C20), and the other three telomerase-positive polyps were obtained from patients diagnosed as negative for carcinoma (patients P6, P7, and P11) ( Table 1 ). In the 23 normal mucosa samples from 23 non-HNPCC patients (patients C6-C22 and P1-P6), 22 samples were negative while one was weakly positive for telomerase activity ( Table 1 ). The weak telomerase activity in the normal mucosa specimens may be explained by the presence of regenerating somatic cells (23) .
Telomerase activity in HNPCC patients. Among the 28 carcinoma samples from 24 HNPCC patients (patients H1-H20 and C1-C4; Table 1 ), 27 were found to be positive for telomerase activity. The absence of telomerase activity in one tumor sample was not due to the presence of inhibitors in the extract, since mixing it with a telomerase-positive HeLa cell extract did not inhibit the telomerase activity of the HeLa extract (data not Tissue extracts of normal mucosa (N), polyp (P), and different sites within the tumor (T1 and T2) from patient C19 were assayed for telomerase activity. For each tissue sample, 0.5 g protein of tissue extract was used for telomerase activity assay as described in the ''Materials and Methods'' section. Three concentrations of HeLa protein (range, 0.005-0.5 g) were assayed in parallel to serve as a positive control for comparison.
shown). Interestingly, eight of the 24 normal mucosa samples were positive for telomerase activity. When these normal mucosa samples were compared with the adjacent cancer tissues, four (patients H1, H9, H19, and C3) were found to have weaker telomerase activity than their adjacent tumors tissues. However, four normal mucosa samples (patients H4, H12, H18, and C2) were found to have levels of telomerase activity comparable with those of the adjacent tumors. Histologic examination of the eight normal mucosa samples did not reveal the presence of cancer cells, infiltrated lymphocytes, dysplasia, or any tissue abnormality (data not shown). Therefore, the telomerase activity detected in these normal tissues could not be accounted for by the presence of cancer cells or lymphocytes in the sample.
Comparison of telomerase activity in normal and cancer tissues of non-HNPCC and HNPCC patients. In addition to comparing telomerase activity between several tissues samples from individual patients, we also compared telomerase activity in corresponding tissue types from non-HNPCC and HNPCC patients. For the normal tissue, significantly more telomerasepositive specimens were seen in HNPCC patients (33%; 95% CI ‫ס‬ 17%-55%) than in non-HNPCC patients (4%; 95% CI ‫ס‬ 0%-16%) (P for Fisher's exact test ‫ס‬ .0226), whereas for the carcinoma tissue, there was no significant difference between these two groups (P for Fisher's exact test ‫ס‬ .1300).
Discussion
HNPCC comprises approximately 5% of all colorectal cancers and is an autosomal-dominant inherited syndrome (1, 2) . Recent studies (3, 4) have shown that most cases of HNPCC are due to the inheritance of germline mutations in genes that encode proteins required for DNA mismatch repair. Since defects of mismatch repair may favor malignant transformation, it has been hypothesized that the formation of cancer in HNPCC patients would not require the reactivation of telomerase (24) . Examination of telomerase activity in tumor tissues of HNPCC patients does not support the above postulate. Instead, HNPCC, like other sporadic colorectal cancers, acquires telomerase expression during tumor progression (24, 25) .
An alternative hypothesis for the involvement of telomerase in the development of HNPCC is that the genetic defect in HNPCC facilitates the activation of telomerase, thus allowing cells to overcome replicative senescence. Such a process may promote cancer development and account for the cancer predisposition of individuals with HNPCC syndrome. According to this postulate, telomerase may be reactivated in the normal and precancerous tissues of these individuals. We obtained precancerous tissues (polyps) from patients without HNPCC syndrome, but we were unable to obtain such tissues from HNPCC patients for comparative study. However, we found that, whereas a substantial fraction (i.e., eight of 24) of normal tissue specimens from HNPCC patients were positive for telomerase activity, only one of the 23 specimens of normal mucosa tissue from non-HNPCC patients were positive for telomerase activity (P ‫ס‬ .0226). Therefore, our results support the postulate that the genetic defect in HNPCC is associated with facilitation of telomerase activity.
Although it is well documented that telomerase activity is detected in the majority of cancers but rarely in normal somatic tissues, studies (23, (26) (27) (28) have demonstrated that some types of somatic cells express low levels of telomerase activity. In particular, physiologically regenerating somatic cells, such as hematopoietic cells, epithelial cells of skin or intestine, and endometrial cells, have been shown to express telomerase activity (26) (27) (28) . In this study, telomerase activity was detected in a significant fraction of normal mucosa from HNPCC patients. The possibility that the telomerase activity detected in these normal mucosa may represent false positivity in the TRAP assay was ruled out by reproducing the assay results after sample decoding. The possibility that these normal mucosa samples may contain cancer cells, infiltrated lymphoid cells, or aberrant dysplasia was evaluated by histologic examination. All of the eight telomerase-positive normal mucosa samples had no detectable cancer cells or lymphocytes, and there was no recognizable abnormality. These results plus the fact that normal mucosa samples were collected in the same way from HNPCC and non-HNPCC syndrome colorectal cancer patients suggest that the telomerase activity observed in a substantial fraction of normal mucosa specimens from HNPCC patients is unique for this group of patients.
At present, the underlying mechanism of telomerase reactivation in the normal tissues of certain HNPCC patients is not known. One possible explanation is that a unique class of genetic defect in HNPCC contributes directly to telomerase reactivation. Alternatively, a deficiency in mismatch repair may lead to acquisition of secondary mutations that activate telomerase indirectly. In a subset of HNPCC patients, widespread mutations and defects in mismatch repair have been found in both the tumor and normal tissues (29) . It would be interesting to know whether this subset of HNPCC patients express telomerase activity in their normal tissues. Further studies of the precise genetic defects and mismatch repair capacity in patients with or without telomerase activity in their somatic tissues should provide valuable information with regard to the mechanism of telomerase reactivation in HNPCC patients.
